Portal de Periódicos da CAPES

Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: A pilot study

2010; Wiley; Volume: 45; Issue: 6 Linguagem: Inglês

10.1002/ppul.21138

8755-6863

Batia Weiss, Yoram Bujanover, Y. Yahav, Daphna Vilozni, Elizabeth Fireman, Ori Efrati,

Gut microbiota and health

Abstract Objective Probiotics reduce intestinal inflammation in, and Lactobacillus GG (LGG) reduces pulmonary exacerbation rate cystic fibrosis (CF) patients. We intended to determine the effect of a mixed probiotic preparation on pulmonary exacerbations and inflammatory characteristics of the sputum in CF patients. Study Design A prospective pilot study of 10 CF patients with mild–moderate lung disease and Pseudomonas aeruginosa colonization, treated with probiotics for 6 months. Pulmonary function tests (PFT's), sputum cultures with semi‐quantitative bacterial analysis, and sputum neutrophil count and interleukin‐8 (IL‐8) levels were compared to pre‐treatment and post‐treatment values. The rate of pulmonary exacerbations was compared to 2 years prior to the study. Results The exacerbation rate was significantly reduced in comparison to the previous 2 years and to 6 months post‐treatment ( P = 0.002). PFT's have not changed at the end of treatment and during 6 months post‐treatment. No change in sputum bacteria, neutrophil count, and IL‐8 levels was observed. Conclusion Probiotics reduce pulmonary exacerbations rate in patients with CF. Probiotics may have a preventive potential for pulmonary deterioration in CF patients. Pediatr Pulmonol. 2010; 45:536–540. © 2010 Wiley‐Liss, Inc.